Avonex® IFN-β-1a im. weekly RRMS and 'early therapy' in patients with an initial demyelinating event and high risk of occurrence of clinically definite MS Rebif® IFN-β-1a sc. three times a ...

Relapsing-remitting multiple sclerosis is a type of multiple sclerosis ... MS is a chronic, progressive condition of the central nervous system (CNS) in which your immune system attacks myelin ...

Multiple sclerosis was first described ... Clinically, MS is classified into four phenotypes, including relapsing-remitting, secondary-progressive, progressive-relapsing, and primary progressive ...

Multiple sclerosis (MS ... They help change relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) in people with active disease. MS is active when a relapse has occurred or new ...

Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS).

A Phase 2 clinical trial testing obexelimab in adults with relapsing types of multiple sclerosis is now recruiting ...

If you've been diagnosed with multiple sclerosis (MS), it's time to start exploring treatment options. You've got a lot of them, everything from disease-modifying therapies and drugs that help manage ...

RRMS is the most common type of multiple sclerosis ... including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.